Drug Search Results
More Filters [+]

Ocaratuzumab

Alternative Names: ocaratuzumab
Latest Update: 2022-05-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CD20 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mentrik Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ocaratuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Follicular Lymphoma|Lymphoma, B-Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MEN-001

P1

Unknown status

Follicular Lymphoma|Lymphoma, B-Cell

2015-12-01

Recent News Events